FdaApplication
NDA 021064
Identifiers
- fda_app_no: NDA021064
Properties
| Property | Value |
|---|---|
| applicant_name | LANTHEUS MEDICAL IMAGING INC |
| application_type | NDA |
| approval_date | 2001-07-31 |
Revenue by product
DEFINITY
| Period | Revenue |
|---|---|
| Q4 2025 | $85.3M |
| Q3 2025 | $81.8M |
| Q2 2025 | $83.9M |
| Q1 2025 | $79.2M |
| Q4 2024 | $86.2M |
| Q3 2024 | $77.0M |
| Q2 2024 | $78.1M |
| Q1 2024 | $76.6M |
| Q4 2023 | $73.1M |
| Q3 2023 | $67.3M |
| Q2 2023 | $70.5M |
| Q1 2023 | $68.8M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DEFINITY | PERFLUTREN | 13.04MG/2ML (6.52MG/ML) | INJECTABLE;INTRAVENOUS |
| DEFINITY RT | PERFLUTREN | 13.04MG/2ML (6.52MG/ML) | INJECTABLE;INTRAVENOUS |
2 products